121 related articles for article (PubMed ID: 37984714)
41. Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma.
Nanda R; Boulware D; Baz R; Portman D; Yu HM; Jim H; Johnstone PAS
Acta Oncol; 2020 Aug; 59(8):983-987. PubMed ID: 32496846
[No Abstract] [Full Text] [Related]
42. From guidelines to real world: results from the National Multiple Myeloma Registry in Uruguay on 222 newly diagnosed multiple myeloma patients from 2012 to 2015.
Riva E; Bove V; Villano F; Mori M; Córdoba C; Noria A; Petruskevicius P; Cardeza A; Díaz L
Curr Med Res Opin; 2019 Jul; 35(7):1197-1203. PubMed ID: 30621522
[No Abstract] [Full Text] [Related]
43. A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Norden AD; Korytowsky B; You M; Kim Le T; Dastani H; Bobiak S; Singh P
J Manag Care Spec Pharm; 2019 Apr; 25(4):428-436. PubMed ID: 30917077
[TBL] [Abstract][Full Text] [Related]
44. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.
Blimark CH; Turesson I; Genell A; Ahlberg L; Björkstrand B; Carlson K; Forsberg K; Juliusson G; Linder O; Mellqvist UH; Nahi H; Kristinsson SY;
Haematologica; 2018 Mar; 103(3):506-513. PubMed ID: 29217784
[TBL] [Abstract][Full Text] [Related]
45. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Damron EP; Qazilbash MH; Fang PQ; Wu SY; Dabaja BS; Rondon G; Hosing C; Champlin RE; Bashir Q; Shpall EJ; Knafl MK; Lee HC; Manasanch EE; Patel K; Thomas SK; Orlowski RZ; Weber DM; Pinnix CC; Gunther JR
Transplant Cell Ther; 2023 Jan; 29(1):37.e1-37.e7. PubMed ID: 37753818
[TBL] [Abstract][Full Text] [Related]
46. Stability of Spinal Bone Lesions in Patients With Multiple Myeloma After Radiotherapy-A Retrospective Analysis of 130 Cases.
Lang K; König L; Bruckner T; Förster R; Sprave T; Schlampp I; Bostel T; Welte S; Nicolay NH; Debus J; Rief H
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e99-e107. PubMed ID: 28993162
[TBL] [Abstract][Full Text] [Related]
47. Physician differences in managing postmenopausal osteoporosis: results from the POSSIBLE US™ treatment registry study.
Lukert B; Satram-Hoang S; Wade S; Anthony M; Gao G; Downs R
Drugs Aging; 2011 Sep; 28(9):713-27. PubMed ID: 21913737
[TBL] [Abstract][Full Text] [Related]
48. Palliative radiotherapy in patients with multiple myeloma.
Yaneva MP; Goranova-Marinova V; Goranov S
J BUON; 2006; 11(1):43-8. PubMed ID: 17318951
[TBL] [Abstract][Full Text] [Related]
49. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
[TBL] [Abstract][Full Text] [Related]
50. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
51. Feasibility and efficacy of local radiotherapy with concurrent novel agents in patients with multiple myeloma.
Shin SM; Chouake RJ; Sanfilippo NJ; Rapp TB; Cook P; Formenti SC; Mazumder A; Silverman JS
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):480-4. PubMed ID: 25176474
[TBL] [Abstract][Full Text] [Related]
52. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K; Moore E; McQuilten Z; Wood E; Augustson B; Blacklock H; Ho J; Horvath N; King T; McNeil J; Mollee P; Quach H; Reid CM; Rosengarten B; Walker P; Spencer A
BMC Med Res Methodol; 2016 Nov; 16(1):151. PubMed ID: 27829380
[TBL] [Abstract][Full Text] [Related]
53. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA.
Thumallapally N; Meshref A; Mousa M; Terjanian T
BMC Cancer; 2017 Jan; 17(1):13. PubMed ID: 28056880
[TBL] [Abstract][Full Text] [Related]
54. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
Dytfeld D; Wróbel T; Jamroziak K; Kubicki T; Robak P; Walter-Croneck A; Czyż J; Tyczyńska A; Druzd-Sitek A; Giannopoulos K; Nowicki A; Szczepaniak T; Łojko-Dankowska A; Matuszak M; Gil L; Puła B; Rybka J; Majcherek M; Usnarska-Zubkiewicz L; Szukalski Ł; Końska A; Zaucha JM; Walewski J; Mikulski D; Czabak O; Robak T; Lahoud OB; Zonder JA; Griffith K; Stefka A; Major A; Derman BA; Jakubowiak AJ
Lancet Oncol; 2023 Feb; 24(2):139-150. PubMed ID: 36642080
[TBL] [Abstract][Full Text] [Related]
55. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
56. Real-world clinical experience in the Connect
Mato A; Nabhan C; Kay NE; Weiss MA; Lamanna N; Kipps TJ; Grinblatt DL; Flinn IW; Kozloff MF; Flowers CR; Farber CM; Kiselev P; Swern AS; Sullivan K; Flick ED; Sharman JP
Br J Haematol; 2016 Dec; 175(5):892-903. PubMed ID: 27861736
[TBL] [Abstract][Full Text] [Related]
57. Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM; Blacklock H; Wellard C; Spearing R; Merriman L; Poplar S; George A; Baker B; Chan H; McQuilten ZK; Wood EM; Spencer A;
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e762-e769. PubMed ID: 35501256
[TBL] [Abstract][Full Text] [Related]
58. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
[TBL] [Abstract][Full Text] [Related]
59. Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution.
Matuschek C; Ochtrop TA; Bölke E; Ganswindt U; Fenk R; Gripp S; Kröpil P; Gerber PA; Kammers K; Hamilton J; Orth K; Budach W
Radiat Oncol; 2015 Mar; 10():71. PubMed ID: 25889851
[TBL] [Abstract][Full Text] [Related]
60. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Hájek R; Jarkovsky J; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Campioni M; DeCosta L; Treur M; Gonzalez-McQuire S; Bouwmeester W
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e219-e240. PubMed ID: 29793653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]